Progression-free survival in patients with NHL (A) and MM (B) stratified by treatment group
A progression-free survival (PFS) event was defined as a report of disease progression, disease relapse, or death due to any cause. Assessment of PFS over 5 years showed no statistically significant difference in patients with non-Hodgkin’s lymphoma (A) (log-rank, P = .343; Wilcoxon, P = .396) or multiple myeloma (MM) (B) between the 2 treatment groups. In patients with MM, a non-significant (log-rank, P = .061; Wilcoxon, P = .138) trend toward shorter PFS in patients treated with plerixafor than in those receiving placebo.